|
WO1997006121A1
(en)
|
1995-08-04 |
1997-02-20 |
Jennings, Norman, T. |
Compositions and method for controlling odor in organic waste material
|
|
GB9600384D0
(en)
|
1996-01-09 |
1996-03-13 |
Nyfotek As |
Dna glycosylases
|
|
EP1235914A2
(en)
|
1999-11-24 |
2002-09-04 |
Joseph Rosenecker |
Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
|
|
US20040003420A1
(en)
|
2000-11-10 |
2004-01-01 |
Ralf Kuhn |
Modified recombinase
|
|
US20050222030A1
(en)
|
2001-02-21 |
2005-10-06 |
Anthony Allison |
Modified annexin proteins and methods for preventing thrombosis
|
|
WO2002068676A2
(en)
|
2001-02-27 |
2002-09-06 |
University Of Rochester |
METHODS AND COMPOSITIONS FOR MODIFYING APOLIPOPROTEIN B mRNA EDITING
|
|
AU2002330714A1
(en)
|
2001-05-30 |
2003-01-02 |
Biomedical Center |
In silico screening for phenotype-associated expressed sequences
|
|
US7300829B2
(en)
|
2003-06-02 |
2007-11-27 |
Applied Materials, Inc. |
Low temperature process for TFT fabrication
|
|
WO2010132092A2
(en)
|
2009-05-12 |
2010-11-18 |
The Scripps Research Institute |
Cytidine deaminase fusions and related methods
|
|
US20110104787A1
(en)
|
2009-11-05 |
2011-05-05 |
President And Fellows Of Harvard College |
Fusion Peptides That Bind to and Modify Target Nucleic Acid Sequences
|
|
EP2513296A4
(en)
|
2009-12-18 |
2013-05-22 |
Univ Leland Stanford Junior |
USE OF CYTIDINE DAMINASE ASSOCIATED ACTIVITIES TO PROMOTE DEMETHYLATION AND CELL REPROGRAMMEIRING
|
|
WO2012004778A1
(en)
|
2010-07-09 |
2012-01-12 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Method for in-vitro monitoring of neuronal disorders and use thereof
|
|
CA3205636A1
(en)
|
2011-04-20 |
2012-10-26 |
University Of Washington Through Its Center For Commercialization |
Beta-2 microglobulin-deficient cells
|
|
KR102096534B1
(ko)
|
2011-09-28 |
2020-04-03 |
에라 바이오테크, 에스.에이. |
분할된 인테인 및 그의 이용
|
|
CN103088008B
(zh)
|
2011-10-31 |
2014-08-20 |
中国科学院微生物研究所 |
胞苷脱氨酶及其编码基因和它们的应用
|
|
WO2013126729A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Use of the cd2 signaling domain in second-generation chimeric antigen receptors
|
|
US20160289674A1
(en)
|
2012-04-02 |
2016-10-06 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of membrane proteins
|
|
FI2838548T3
(fi)
|
2012-04-17 |
2023-10-02 |
Univ Washington Through Its Center For Commercialization |
HLA:n luokan II puutteelliset solut, HLA:n luokan II puutteelliset solut, jotka kykenevät ilmentämään HLA:n luokan II proteiineja, ja niiden käytöt
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
US20150017136A1
(en)
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
|
WO2013188037A2
(en)
|
2012-06-11 |
2013-12-19 |
Agilent Technologies, Inc |
Method of adaptor-dimer subtraction using a crispr cas6 protein
|
|
EP3431497B1
(en)
|
2012-06-27 |
2022-07-27 |
The Trustees of Princeton University |
Split inteins, conjugates and uses thereof
|
|
PL3360964T3
(pl)
|
2012-12-06 |
2020-03-31 |
Sigma-Aldrich Co. Llc |
Modyfikacja i regulacja genomu oparta na crispr
|
|
WO2014093655A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
|
US20140273230A1
(en)
|
2013-03-15 |
2014-09-18 |
Sigma-Aldrich Co., Llc |
Crispr-based genome modification and regulation
|
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
|
FI2997141T3
(fi)
|
2013-05-13 |
2022-12-15 |
|
CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä
|
|
WO2014186686A2
(en)
|
2013-05-17 |
2014-11-20 |
Two Blades Foundation |
Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
|
|
US9267135B2
(en)
|
2013-06-04 |
2016-02-23 |
President And Fellows Of Harvard College |
RNA-guided transcriptional regulation
|
|
WO2014197748A2
(en)
|
2013-06-05 |
2014-12-11 |
Duke University |
Rna-guided gene editing and gene regulation
|
|
EP3019595A4
(en)
|
2013-07-09 |
2016-11-30 |
|
THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS
|
|
EP3666892A1
(en)
|
2013-07-10 |
2020-06-17 |
President and Fellows of Harvard College |
Orthogonal cas9 proteins for rna-guided gene regulation and editing
|
|
WO2015021426A1
(en)
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
A crispr/cas system-based novel fusion protein and its application in genome editing
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
WO2015069922A2
(en)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
|
JP7103750B2
(ja)
|
2013-12-12 |
2022-07-20 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
EP3835419A1
(en)
|
2013-12-12 |
2021-06-16 |
The Regents of The University of California |
Methods and compositions for modifying a single stranded target nucleic acid
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
WO2015092024A2
(en)
|
2013-12-20 |
2015-06-25 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
EP3115457B1
(en)
|
2014-03-05 |
2019-10-02 |
National University Corporation Kobe University |
Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
|
|
JP6681837B2
(ja)
|
2014-03-11 |
2020-04-15 |
セレクティスＣｅｌｌｅｃｔｉｓ |
同種移植に適合するｔ細胞を作製するための方法
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
EP3155116A4
(en)
|
2014-06-10 |
2017-12-27 |
Massachusetts Institute Of Technology |
Method for gene editing
|
|
KR20170032406A
(ko)
|
2014-07-15 |
2017-03-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료를 위한 조작된 세포
|
|
US10544201B2
(en)
|
2014-07-31 |
2020-01-28 |
Cellectis |
ROR1 specific multi-chain chimeric antigen receptor
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
EP3186375A4
(en)
|
2014-08-28 |
2019-03-13 |
North Carolina State University |
Novel CAS9 PROTEINS AND CHARACTERISTICS FOR DNA TARGETING AND GENOME EDITING
|
|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
BR112017007765B1
(pt)
|
2014-10-14 |
2023-10-03 |
Halozyme, Inc |
Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
|
|
WO2016061368A1
(en)
|
2014-10-15 |
2016-04-21 |
The Children's Hospital Of Philadelphia |
Compositions and methods for treating b-lymphoid malignancies
|
|
US10258697B2
(en)
|
2014-10-29 |
2019-04-16 |
Massachusetts Eye And Ear Infirmary |
Efficient delivery of therapeutic molecules in vitro and in vivo
|
|
US20170335331A1
(en)
|
2014-10-31 |
2017-11-23 |
The Trustees Of The University Of Pennsylvania |
Altering Gene Expression in CART Cells and Uses Thereof
|
|
PT3216867T
(pt)
|
2014-11-04 |
2020-07-16 |
Univ Kobe Nat Univ Corp |
Método para modificar a sequência de genoma para introduzir mutação específica a sequência de adn alvo por reação de remoção de bases, e complexo molecular nele utilizado
|
|
MA40921A
(fr)
|
2014-11-05 |
2017-09-12 |
Abbvie Stemcentrx Llc |
Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
|
|
WO2016075612A1
(en)
|
2014-11-12 |
2016-05-19 |
Rinat Neuroscience Corp. |
Inhibitory chimeric antigen receptors
|
|
HRP20191873T1
(hr)
|
2014-12-12 |
2020-01-24 |
Bluebird Bio, Inc. |
Kimerni antigenski receptori
|
|
EP3234134B1
(en)
|
2014-12-17 |
2020-05-27 |
ProQR Therapeutics II B.V. |
Targeted rna editing
|
|
WO2016100955A2
(en)
|
2014-12-20 |
2016-06-23 |
Identifygenomics, Llc |
Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using crispr/cas system proteins
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
MA41613A
(fr)
|
2015-02-23 |
2018-01-02 |
Abbvie Stemcentrx Llc |
Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
|
|
JP7237449B2
(ja)
|
2015-02-27 |
2023-03-13 |
アイセル・ジーン・セラピューティクス・エルエルシー |
血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
KR20230156800A
(ko)
|
2015-03-03 |
2023-11-14 |
더 제너럴 하스피탈 코포레이션 |
변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
|
|
JP2018509148A
(ja)
|
2015-03-11 |
2018-04-05 |
セレクティスＣｅｌｌｅｃｔｉｓ |
患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法
|
|
AU2016243583B2
(en)
|
2015-03-27 |
2022-03-10 |
President And Fellows Of Harvard College |
Modified T cells and methods of making and using the same
|
|
JP2018522249A
(ja)
|
2015-04-24 |
2018-08-09 |
エディタス・メディシン、インコーポレイテッド |
Ｃａｓ９分子／ガイドｒｎａ分子複合体の評価
|
|
CN107921148A
(zh)
|
2015-05-08 |
2018-04-17 |
哈佛学院校长同事会 |
通用供体干细胞和相关方法
|
|
US20180291372A1
(en)
|
2015-05-14 |
2018-10-11 |
Massachusetts Institute Of Technology |
Self-targeting genome editing system
|
|
CN106011104B
(zh)
|
2015-05-21 |
2019-09-27 |
清华大学 |
利用拆分Cas系统进行基因编辑和表达调控方法
|
|
WO2016196388A1
(en)
|
2015-05-29 |
2016-12-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
EP3331582A4
(en)
|
2015-05-29 |
2019-08-07 |
Agenovir Corporation |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRANSPLANTATION CELLS
|
|
TWI906646B
(zh)
|
2015-06-18 |
2025-12-01 |
美商博得學院股份有限公司 |
降低脫靶效應的ｃｒｉｓｐｒ酶突變
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
JP7033453B2
(ja)
|
2015-06-30 |
2022-03-10 |
セレクティス |
特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法
|
|
JP7044373B2
(ja)
|
2015-07-15 |
2022-03-30 |
ラトガース，ザ ステート ユニバーシティ オブ ニュージャージー |
ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途
|
|
US20170020922A1
(en)
|
2015-07-16 |
2017-01-26 |
Batu Biologics Inc. |
Gene editing for immunological destruction of neoplasia
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
CA2997551A1
(en)
|
2015-09-04 |
2017-03-09 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use
|
|
AU2016323985B2
(en)
|
2015-09-17 |
2022-12-15 |
Novartis Ag |
CAR T cell therapies with enhanced efficacy
|
|
US11008555B2
(en)
|
2015-09-17 |
2021-05-18 |
The Regents Of The University Of California |
Variant Cas9 polypeptides comprising internal insertions
|
|
IL310721B2
(en)
|
2015-10-23 |
2025-11-01 |
Harvard College |
Nucleobase editors and uses thereof
|
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
|
BR112018008442A2
(pt)
|
2015-11-05 |
2018-11-06 |
Juno Therapeutics Inc |
receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
|
|
BR112018008971A2
(pt)
|
2015-11-06 |
2018-11-27 |
Crispr Therapeutics Ag |
materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a
|
|
CN109715801B
(zh)
|
2015-12-01 |
2022-11-01 |
克里斯普治疗股份公司 |
用于治疗α1抗胰蛋白酶缺乏的材料和方法
|
|
WO2017093969A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
PT3408292T
(pt)
|
2016-01-29 |
2023-07-19 |
Univ Princeton |
Inteínas divididas com excecional atividade de splicing
|
|
EP3423580A1
(en)
|
2016-03-04 |
2019-01-09 |
Editas Medicine, Inc. |
Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
|
|
US11512311B2
(en)
|
2016-03-25 |
2022-11-29 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
|
|
LT3436077T
(lt)
|
2016-03-30 |
2025-06-25 |
Intellia Therapeutics, Inc. |
Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams
|
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
EP3443002A4
(en)
|
2016-04-14 |
2019-12-04 |
Bluebird Bio, Inc. |
SYSTEMS FOR RECOVERED CHIMERIC ANTIGEN RECEPTORS
|
|
KR20260004568A
(ko)
|
2016-04-19 |
2026-01-08 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규한 crispr 효소 및 시스템
|
|
AU2017257274B2
(en)
|
2016-04-19 |
2023-07-13 |
Massachusetts Institute Of Technology |
Novel CRISPR enzymes and systems
|
|
KR20190039703A
(ko)
|
2016-07-05 |
2019-04-15 |
더 존스 홉킨스 유니버시티 |
Crispr/cas9-기반 조성물 및 망막 변성을 치료하기 위한 방법
|
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
|
CN110214183A
(zh)
|
2016-08-03 |
2019-09-06 |
哈佛大学的校长及成员们 |
腺苷核碱基编辑器及其用途
|
|
KR102546839B1
(ko)
|
2016-08-03 |
2023-06-23 |
워싱턴 유니버시티 |
키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집
|
|
WO2018031683A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
|
EP4485466A3
(en)
|
2016-08-17 |
2025-04-02 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
CN110352244B
(zh)
|
2016-09-01 |
2023-03-21 |
ProQR治疗上市公司Ⅱ |
化学修饰的编辑rna的单链寡核苷酸
|
|
KR102622411B1
(ko)
|
2016-10-14 |
2024-01-10 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
|
WO2018085690A1
(en)
|
2016-11-04 |
2018-05-11 |
Bluebird Bio, Inc. |
Anti-bcma car t cell compositions
|
|
EP3538561A4
(en)
|
2016-11-11 |
2020-10-21 |
The Regents of The University of California |
RNA-GUIDED VARIANT POLYPEPTIDES AND THEIR METHODS OF USE
|
|
CN107043779B
(zh)
|
2016-12-01 |
2020-05-12 |
中国农业科学院作物科学研究所 |
一种CRISPR/nCas9介导的定点碱基替换在植物中的应用
|
|
SG10202106058WA
(en)
|
2016-12-08 |
2021-07-29 |
Intellia Therapeutics Inc |
Modified guide rnas
|
|
TWI851534B
(zh)
|
2016-12-22 |
2024-08-11 |
美商英特利亞醫療公司 |
用於治療α-１抗胰蛋白酶缺乏症之組合物及方法
|
|
GB201622044D0
(en)
|
2016-12-22 |
2017-02-08 |
Ucl Business Plc |
T cell-targeted T cells
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
KR20230125856A
(ko)
|
2016-12-23 |
2023-08-29 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Pcsk9의 유전자 편집
|
|
EP3565608A4
(en)
|
2017-01-05 |
2020-12-16 |
Rutgers, The State University of New Jersey |
TARGETED GENE EDITING PLATFORM INDEPENDENT OF BICATENARY DNA BREAKAGE AND ITS USES
|
|
WO2018132479A1
(en)
|
2017-01-10 |
2018-07-19 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
|
ES2912408T3
(es)
|
2017-01-26 |
2022-05-25 |
Novartis Ag |
Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
|
|
WO2018152197A1
(en)
|
2017-02-15 |
2018-08-23 |
Massachusetts Institute Of Technology |
Dna writers, molecular recorders and uses thereof
|
|
RU2019130504A
(ru)
|
2017-02-28 |
2021-03-30 |
Вор Байофарма, Инк. |
Композиции и способы ингибирования линиеспецифических белков
|
|
US12390514B2
(en)
*
|
2017-03-09 |
2025-08-19 |
President And Fellows Of Harvard College |
Cancer vaccine
|
|
US11542496B2
(en)
|
2017-03-10 |
2023-01-03 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
|
KR20240116572A
(ko)
|
2017-03-23 |
2024-07-29 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
|
|
US20200101108A1
(en)
|
2017-03-31 |
2020-04-02 |
The Board Of Trustees Of The Le-Land Standford Junior University |
Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
|
|
CN106916852B
(zh)
|
2017-04-13 |
2020-12-04 |
上海科技大学 |
一种碱基编辑系统及其构建和应用方法
|
|
US11591589B2
(en)
|
2017-04-21 |
2023-02-28 |
The General Hospital Corporation |
Variants of Cpf1 (Cas12a) with altered PAM specificity
|
|
CN118948892A
(zh)
|
2017-05-01 |
2024-11-15 |
朱诺治疗学股份有限公司 |
细胞疗法与免疫调节化合物的组合
|
|
US11866697B2
(en)
|
2017-05-18 |
2024-01-09 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
WO2018213726A1
(en)
|
2017-05-18 |
2018-11-22 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
US20200171135A1
(en)
|
2017-05-24 |
2020-06-04 |
The Regents Of The University Of California |
CMV Vaccine and Method of Making and Using the Same
|
|
EP3630849A4
(en)
|
2017-05-25 |
2021-01-13 |
The General Hospital Corporation |
BIPARTITE BASIC EDITOR (BBE) AND TYPE II-C-CAS9 ZINC FINGER EDITOR ARCHITECTURES
|
|
CN110944652A
(zh)
|
2017-06-12 |
2020-03-31 |
爱莫里大学 |
T细胞抗原靶向的嵌合抗原受体(car)以及在细胞疗法中的用途
|
|
WO2019005886A1
(en)
|
2017-06-26 |
2019-01-03 |
The Broad Institute, Inc. |
CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS
|
|
KR102761791B1
(ko)
|
2017-06-26 |
2025-02-05 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적화된 핵산 편집을 위한 crispr/cas-아데닌 데아미나아제 기반 조성물, 시스템 및 방법
|
|
US10392616B2
(en)
|
2017-06-30 |
2019-08-27 |
Arbor Biotechnologies, Inc. |
CRISPR RNA targeting enzymes and systems and uses thereof
|
|
CA3069527A1
(en)
|
2017-07-12 |
2019-01-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for treatment of cancers harboring an h3k27m mutation
|
|
US11740242B2
(en)
|
2017-07-14 |
2023-08-29 |
Dana-Farber Cancer Institute, Inc. |
Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
|
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
|
CA3073448A1
(en)
|
2017-08-23 |
2019-02-28 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases with altered pam specificity
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
WO2019071274A1
(en)
|
2017-10-06 |
2019-04-11 |
Oregon Health & Science University |
Compositions and methods for editing rna
|
|
KR20250107288A
(ko)
|
2017-10-16 |
2025-07-11 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
EP3723774A4
(en)
|
2017-12-15 |
2021-09-08 |
The Board of Trustees of the Leland Stanford Junior University |
COMPOSITIONS AND METHODS OF INHIBITION OF T-CELL EXHAUSTATION
|
|
CN109957569B
(zh)
|
2017-12-22 |
2022-10-25 |
苏州齐禾生科生物科技有限公司 |
基于cpf1蛋白的碱基编辑系统和方法
|
|
CA3177757A1
(en)
*
|
2018-02-16 |
2019-08-22 |
Kite Pharma, Inc. |
Modified pluripotent stem cells and methods of making and use
|
|
WO2019178225A2
(en)
*
|
2018-03-13 |
2019-09-19 |
Regents Of The University Of Minnesota |
Lymphohematopoietic engineering using cas9 base editors
|
|
US20210363518A1
(en)
|
2018-03-19 |
2021-11-25 |
University Of Massachusetts |
Modified guide rnas for crispr genome editing
|
|
EP3781176A4
(en)
|
2018-04-09 |
2022-05-25 |
The Trustees of the University of Pennsylvania |
METHODS AND COMPOSITIONS USING A VIRAL VECTOR FOR THE EXPRESSION OF A TRANSGENE AND AN EFFECTOR
|
|
US12473342B2
(en)
|
2018-04-27 |
2025-11-18 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis
|
|
AU2019265019B2
(en)
|
2018-05-11 |
2025-11-06 |
Beam Therapeutics Inc. |
Methods of substituting pathogenic amino acids using programmable base editor systems
|
|
CN119570787A
(zh)
|
2018-05-11 |
2025-03-07 |
比姆医疗股份有限公司 |
使用可编程碱基编辑器系统遏止病原性突变的方法
|
|
KR20250133482A
(ko)
|
2018-05-11 |
2025-09-05 |
빔 테라퓨틱스, 인크. |
프로그래밍가능한 염기 편집기 시스템을 이용하여 단일 뉴클레오티드 다형성을 편집하는 방법
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
CN110616189B
(zh)
|
2018-06-20 |
2022-02-18 |
西安桑尼赛尔生物医药有限公司 |
通用型靶向cd19抗原嵌合受体t细胞的制备及其应用
|
|
CN108753823B
(zh)
|
2018-06-20 |
2022-09-23 |
李广磊 |
利用碱基编辑技术实现基因敲除的方法及其应用
|
|
WO2020010239A1
(en)
|
2018-07-06 |
2020-01-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric antigen receptor polypeptides and methods of using same
|
|
CN108949825A
(zh)
|
2018-07-30 |
2018-12-07 |
苏州茂行生物科技有限公司 |
一种靶向her2的car-t细胞的制备方法及应用
|
|
CA3108281A1
(en)
|
2018-08-03 |
2020-02-06 |
Beam Therapeutics Inc. |
Multi-effector nucleobase editors and methods of using same to modify a nucleic acid target sequence
|
|
EP3841203A4
(en)
|
2018-08-23 |
2022-11-02 |
The Broad Institute Inc. |
CAS9 VARIANTS WITH NON-CANONICAL PAM SPECIFICITIES AND THEIR USES
|
|
EP3847254A4
(en)
|
2018-09-07 |
2022-08-10 |
Beam Therapeutics Inc. |
COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM
|
|
CN109295186B
(zh)
|
2018-09-30 |
2023-10-03 |
中山大学 |
一种基于全基因组测序检测腺嘌呤单碱基编辑系统脱靶效应的方法及其在基因编辑中的应用
|
|
EP3886869A4
(en)
|
2018-11-28 |
2022-07-06 |
Forty Seven, Inc. |
GENETICALLY MODIFIED ABLATION-RESISTANT HSPCS
|
|
EP3887521A1
(en)
|
2018-11-29 |
2021-10-06 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
US12454562B2
(en)
|
2018-12-06 |
2025-10-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Regulatable cell surface receptors and related compositions and methods
|
|
CN113454117B
(zh)
|
2018-12-19 |
2025-07-04 |
宾夕法尼亚大学董事会 |
Cd2/5/7敲除抗-cd2/5/7嵌合抗原受体t细胞针对t细胞淋巴瘤和白血病的用途
|
|
EP3911735A4
(en)
|
2019-01-16 |
2023-07-12 |
Beam Therapeutics, Inc. |
MODIFIED IMMUNE CELLS WITH INCREASED ANTINEOPLASTIC ACTIVITY AND RESISTANCE TO IMMUNOSUPPRESSION
|
|
CN109706121A
(zh)
*
|
2019-01-25 |
2019-05-03 |
苏州茂行生物科技有限公司 |
一种基于碱基编辑的通用型car-t细胞及其制备方法和应用
|
|
WO2020160517A1
(en)
|
2019-01-31 |
2020-08-06 |
Beam Therapeutics Inc. |
Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence
|
|
AU2020215730A1
(en)
|
2019-01-31 |
2021-07-29 |
Beam Therapeutics Inc. |
Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors
|
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
|
US20230140953A1
(en)
|
2019-02-13 |
2023-05-11 |
Beam Therapeutics Inc. |
Methods of editing a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease
|
|
JP7693552B2
(ja)
|
2019-02-13 |
2025-06-17 |
ビーム セラピューティクス インク． |
アデノシンデアミナーゼ塩基エディターおよびそれを用いて標的配列中の核酸塩基を改変する方法
|
|
US20220098593A1
(en)
|
2019-02-13 |
2022-03-31 |
Beam Therapeutics Inc. |
Splice acceptor site disruption of a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease
|
|
WO2020168088A1
(en)
|
2019-02-13 |
2020-08-20 |
Beam Therapeutics Inc. |
Compositions and methods for treating glycogen storage disease type 1a
|
|
KR20210126680A
(ko)
|
2019-02-13 |
2021-10-20 |
빔 테라퓨틱스, 인크. |
알파-1 항트립신 결핍증을 치료하기 위한 조성물 및 방법
|
|
CN120174005A
(zh)
*
|
2019-02-13 |
2025-06-20 |
比姆医疗股份有限公司 |
具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞
|
|
CA3128755C
(en)
|
2019-02-13 |
2024-06-04 |
Beam Therapeutics Inc. |
Compositions and methods for treating hemoglobinopathies
|
|
PE20211959A1
(es)
|
2019-02-15 |
2021-09-30 |
Editas Medicine Inc |
Celulas asesinas naturales (nk) modificadas para inmunoterapia
|
|
WO2020176897A1
(en)
|
2019-02-28 |
2020-09-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric antigen receptors and uses thereof
|
|
JP7654557B2
(ja)
|
2019-03-27 |
2025-04-01 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Ｔｎ－ＭＵＣ１キメラ抗原受容体（ＣＡＲ）Ｔ細胞療法
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
EP3965897A4
(en)
|
2019-05-07 |
2023-01-04 |
The Board of Trustees of the Leland Stanford Junior University |
CHEMERA ANTIGEN RECEPTORS TARGETING GLYPICAN-2
|
|
EP3966236A4
(en)
|
2019-05-07 |
2023-05-10 |
The Board of Trustees of the Leland Stanford Junior University |
Enhancement of polypeptides and chimeric antigen receptors via hinge domains
|
|
US20220249697A1
(en)
|
2019-05-20 |
2022-08-11 |
The Broad Institute, Inc. |
Aav delivery of nucleobase editors
|
|
WO2020236964A1
(en)
|
2019-05-20 |
2020-11-26 |
The Trustees Of The University Of Pennsylvania |
Engineered expression of cell surface and secreted sialidase by car t cells for increased efficacy in solid tumors
|
|
AU2020279751A1
(en)
|
2019-05-21 |
2021-12-02 |
Beam Therapeutics Inc. |
Methods of editing a single nucleotide polymorphism using programmable base editor systems
|
|
KR20220015382A
(ko)
|
2019-05-29 |
2022-02-08 |
큐 바이오파마, 인크. |
다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
|
|
WO2021022043A2
(en)
|
2019-07-30 |
2021-02-04 |
Pairwise Plants Services, Inc. |
Morphogenic regulators and methods of using the same
|
|
KR102258713B1
(ko)
|
2019-07-31 |
2021-05-31 |
한양대학교 산학협력단 |
사이토신 염기교정용 조성물 및 이의 용도
|
|
EP4022051A4
(en)
|
2019-08-29 |
2024-01-10 |
Beam Therapeutics Inc. |
COMPOSITIONS AND METHODS FOR NON-TOXIC CONDITIONING
|
|
WO2021042062A2
(en)
|
2019-08-30 |
2021-03-04 |
Joung J Keith |
Combinatorial adenine and cytosine dna base editors
|
|
AU2020344547A1
(en)
|
2019-09-09 |
2022-03-24 |
Beam Therapeutics Inc. |
Novel nucleobase editors and methods of using same
|
|
AU2020466994A1
(en)
|
2019-09-17 |
2022-04-21 |
Rutgers, The State University Of New Jersey |
Highly efficient DNA base editors mediated by RNA-aptamer recruitment for targeted genome modification and uses thereof
|
|
EP4034138A4
(en)
|
2019-09-27 |
2024-07-31 |
Beam Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
|
|
CA3154218A1
(en)
|
2019-10-11 |
2021-04-15 |
Crystal Mackall |
Recombinant polypeptides for regulatable cellular localization
|
|
WO2021081264A1
(en)
|
2019-10-24 |
2021-04-29 |
Pairwise Plants Services, Inc. |
Optimized crispr-cas nucleases and base editors and methods of use thereof
|
|
EP4051788A4
(en)
|
2019-10-30 |
2023-12-06 |
Pairwise Plants Services, Inc. |
TYPE V CRISPR CAS BASE EDITORS AND METHODS OF USE THEREOF
|
|
WO2021087356A1
(en)
|
2019-11-01 |
2021-05-06 |
The Trustees Of The University Of Pennsylvania |
Fibronectin targeting chimeric antigen receptors (cars)
|
|
AU2020388690A1
(en)
|
2019-11-20 |
2022-06-09 |
Cartherics Pty. Ltd. |
Method for providing immune cells with enhanced function
|
|
US20230086199A1
(en)
|
2019-11-26 |
2023-03-23 |
The Broad Institute, Inc. |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
|
IL293946A
(en)
|
2019-12-18 |
2022-08-01 |
Editas Medicine Inc |
Engineered cells for therapy
|
|
US20210230246A1
(en)
|
2020-01-15 |
2021-07-29 |
The Trustees Of The University Of Pennsylvania |
Use of inhibitory chimeric receptors to prevent t cell-induced blood brain barrier damage
|
|
EP4100032B1
(en)
|
2020-02-05 |
2025-10-15 |
The Broad Institute, Inc. |
Gene editing methods for treating spinal muscular atrophy
|
|
EP4100519A2
(en)
|
2020-02-05 |
2022-12-14 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
|
MX2022009827A
(es)
|
2020-02-14 |
2022-09-05 |
Univ Leland Stanford Junior |
Receptores de antigenos quimericos con activacion de cd2.
|
|
JP2023517890A
(ja)
|
2020-03-04 |
2023-04-27 |
スージョウ チー バイオデザイン バイオテクノロジー カンパニー リミテッド |
改善されたシトシン塩基編集システム
|
|
JP2023518395A
(ja)
|
2020-03-19 |
2023-05-01 |
インテリア セラピューティクス，インコーポレイテッド |
指向性ゲノム編集のための方法及び組成物
|
|
EP4132951A4
(en)
|
2020-04-09 |
2025-06-11 |
Verve Therapeutics, Inc. |
CHEMICALLY MODIFIED GENE EDITING GUIDE RNAS WITH CAS12B
|
|
WO2022008935A1
(en)
|
2020-07-10 |
2022-01-13 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
|
US20240247242A1
(en)
|
2020-07-15 |
2024-07-25 |
LifeEDIT Therapeutics, Inc. |
Uracil stabilizing proteins and active fragments and variants thereof and methods of use
|
|
JP2023540797A
(ja)
|
2020-09-11 |
2023-09-26 |
メタゲノミ，インコーポレイテッド |
塩基編集酵素
|
|
MX2023002848A
(es)
|
2020-09-11 |
2023-03-22 |
Lifeedit Therapeutics Inc |
Enzimas modificadoras del acido desoxirribonucleico (adn) y fragmentos activos y sus variantes y metodos de uso.
|
|
WO2022061115A1
(en)
*
|
2020-09-18 |
2022-03-24 |
Vor Biopharma Inc. |
Compositions and methods for cd7 modification
|
|
CA3196831A1
(en)
|
2020-09-25 |
2022-03-31 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
CA3198671A1
(en)
|
2020-10-14 |
2022-04-21 |
Beam Therapeutics Inc. |
Compositions and methods for treating glycogen storage disease type 1a
|
|
IT202000028688A1
(it)
|
2020-11-27 |
2022-05-27 |
Consiglio Nazionale Ricerche |
Varianti della citidina deaminasi per l’editazione di basi
|
|
CA3207144A1
(en)
|
2021-01-05 |
2022-07-14 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
|
WO2022150372A1
(en)
|
2021-01-05 |
2022-07-14 |
Horizon Discovery Ltd. |
Guide rna designs and complexes for type v cas systems
|
|
JP2024502348A
(ja)
|
2021-01-05 |
2024-01-18 |
ホライズン・ディスカバリー・リミテッド |
Ｔｒａｃｒ不含 Ｖ型Ｃａｓシステム用のガイドＲＮＡデザインおよび複合体
|
|
EP4274897A4
(en)
|
2021-01-08 |
2025-03-05 |
The General Hospital Corporation |
GENOMEDITING APPROACHES TO THE TREATMENT OF SPINAL MUSCLE ATROPHY
|
|
CA3208612A1
(en)
|
2021-02-19 |
2022-08-25 |
Beam Therapeutics Inc. |
Recombinant rabies viruses for gene therapy
|
|
EP4313118A4
(en)
|
2021-03-26 |
2025-06-18 |
Beam Therapeutics Inc. |
ADENOSINE DEAMINASE VARIANTS AND THEIR USES
|
|
EP4359541A4
(en)
|
2021-06-23 |
2025-04-30 |
Editas Medicine, Inc. |
Engineered cells for therapy
|
|
US20240327859A1
(en)
|
2021-07-02 |
2024-10-03 |
University Of Maryland, College Park |
Cytidine deaminases and methods of genome editing using the same
|
|
CA3225808A1
(en)
|
2021-07-16 |
2023-01-19 |
David R. Liu |
Context-specific adenine base editors and uses thereof
|
|
AU2022331424A1
(en)
|
2021-08-16 |
2024-02-22 |
Beam Therapeutics Inc. |
Persistent allogeneic modified immune cells and methods of use thereof
|
|
US20240352439A1
(en)
|
2021-09-03 |
2024-10-24 |
The University Of Chicago |
Polypeptides and methods for modifying nucleic acids
|
|
IL311607A
(en)
|
2021-09-22 |
2024-05-01 |
Verve Therapeutics Inc |
PCSK9 or ANGPTL3 gene editing and preparations and methods for using them to treat the disease
|
|
US20230105319A1
(en)
|
2021-09-24 |
2023-04-06 |
Crispr Therapeutics Ag |
PRODRUG INCORPORATED sgRNA SYNTHESIS
|
|
WO2023108107A2
(en)
|
2021-12-10 |
2023-06-15 |
Beam Therapeutics Inc. |
Modified immune cells and methods of using the same
|
|
WO2023125814A1
(zh)
|
2021-12-29 |
2023-07-06 |
华东师范大学 |
腺嘌呤脱氨酶及其应用
|
|
CN119013310A
(zh)
|
2022-02-17 |
2024-11-22 |
正序(上海)生物科技有限公司 |
具有改善的编辑精确度的突变的胞嘧啶脱氨酶
|
|
CN114634923B
(zh)
|
2022-04-07 |
2024-02-23 |
尧唐(上海)生物科技有限公司 |
腺苷脱氨酶、碱基编辑器融合蛋白、碱基编辑器系统及用途
|
|
EP4532704A2
(en)
|
2022-05-26 |
2025-04-09 |
UCB Biopharma SRL |
Novel nucleic acid-editing proteins
|
|
EP4532697A2
(en)
|
2022-06-03 |
2025-04-09 |
Beam Therapeutics Inc. |
Modified regulatory t cells and methods of using the same
|
|
EP4540378A1
(en)
|
2022-06-20 |
2025-04-23 |
CRISPR Therapeutics AG |
Base editing proteins and uses thereof
|
|
AU2023288909A1
(en)
|
2022-06-23 |
2025-01-09 |
Basf Agricultural Solutions Us Llc |
Diversifying base editing
|
|
EP4544035A2
(en)
|
2022-06-27 |
2025-04-30 |
Beam Therapeutics Inc. |
Adenosine deaminase base editors and methods for use thereof
|
|
WO2024040083A1
(en)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Evolved cytosine deaminases and methods of editing dna using same
|
|
KR20250075667A
(ko)
|
2022-09-23 |
2025-05-28 |
기초과학연구원 |
신규한 아데닌 탈아미노효소 변이체 및 이를 사용한 염기 교정 방법
|
|
EP4594486A2
(en)
|
2022-09-26 |
2025-08-06 |
Beam Therapeutics Inc. |
Synthetic polypeptides and uses thereof
|
|
WO2024179426A2
(en)
|
2023-02-28 |
2024-09-06 |
Accuredit Therapeutics (Suzhou) Co., Ltd. |
Deaminases for use in base editing
|
|
EP4688814A1
(en)
|
2023-04-27 |
2026-02-11 |
University of Massachusetts |
Cas-embedded cytidine deaminase ribonucleoprotein complexes having improved base editing specificity and efficiency
|
|
CN121079412A
(zh)
|
2023-04-28 |
2025-12-05 |
比姆医疗股份有限公司 |
经修饰的指导rna
|
|
AU2024303631A1
(en)
|
2023-06-15 |
2025-12-11 |
Beam Therapeutics Inc. |
Methods and compositions for treating alpha-1 antitrypsin deficiency
|
|
CN117965505A
(zh)
|
2023-06-28 |
2024-05-03 |
微光基因(苏州)有限公司 |
工程化的腺苷脱氨酶及碱基编辑器
|